Streetbeat News

EUDA

EUDA Health Holdings Limited

Industry

Medical - Healthcare Information Services

EUDA Health Limited develops digital health platform that offers virtual consults for non-emergency medical issues. The company was founded in 2019 and is based in Singapore. EUDA Health Limited company operates as a subsidiary of Watermark Developments Limited.

Open

3.42

Mkt cap

124M

Volume

32K

High

3.58

P/E Ratio

-5.37

52-wk high

6.30

Low

3.28

Div yield

N/A

52-wk low

1.20

EUDA Holdings and Guangdong Cell Biotech are in preliminary discussions to form a joint venture aimed at advancing biotechnology innovation. This potential strategic partnership could enhance EUDA's position in the biotech sector.

Portfolio Pulse from

December 16, 2024 | 10:15 pm

Euda Health Holdings has filed with the SEC for a $100 million mixed shelf offering, which allows the company to issue various types of securities over time. This move provides Euda with flexibility to raise capital as needed.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 8:10 pm

Diamond Equity Research has initiated coverage on EUDA Health Holdings, highlighting its strategic acquisitions, digital healthcare platform, and expansion in Southeast Asia's healthcare market. The report values EUDA at $6.00 per share, contingent on successful execution.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 12:12 pm

12 health care stocks showed significant movements in Thursday's pre-market session. CNS Pharma (CNSP) saw the highest gain, rising 109.5%, while Gain Therapeutics (GANX) experienced the largest decline, falling 15.5%.

Portfolio Pulse from Benzinga Insights

July 05, 2024 | 2:59 pm

In Tuesday's after-market session, health care stocks saw significant movements. Clover Health Investments, Inogen, and Nektar Therapeutics were among the top gainers, with their stocks rising due to the release of Q1 earnings. Conversely, Treace Medical Concepts, Inspire Medical Systems, and Semler Scientific led the losers, experiencing declines after their Q1 earnings reports. The movements reflect the market's reaction to the latest financial results.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 8:31 pm

EUDA Health Holdings has completed the acquisition of CK Health, paying with 10 million newly issued ordinary shares valued at $15 million. This strategic move aims to expand EUDA's healthcare services and market reach.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 9:10 pm

EUDA Health has regained compliance with Nasdaq's listing requirements, ensuring its continued listing on the exchange. This follows a period where EUDA may have been at risk of delisting due to non-compliance with Nasdaq's standards.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 6:06 am

The article lists the stocks that gained and lost the most in Wednesday's mid-day session. Notable gainers include Cellectis S.A. (NASDAQ:CLLS) due to strategic collaboration and investment agreements with AstraZeneca, and Patriot Transportation Holding, Inc. (NASDAQ:PATI) due to an acquisition agreement with United Petroleum Transports. Notable losers include WeWork Inc. (NYSE:WE) due to reports of nearing bankruptcy, and Paycom Software, Inc. (NYSE:PAYC) due to worse-than-expected third-quarter sales results and lowered FY23 revenue guidance.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 5:59 pm

The article lists the stocks that gained and lost in Tuesday's mid-day session. Notable gainers include SciSparc Ltd., Cardio Diagnostics Holdings, Inc., and Verve Therapeutics, Inc. due to positive news such as patent acceptance and contract acquisition. On the other hand, Kintara Therapeutics, Inc., Galera Therapeutics, Inc., and reAlpha Tech Corp. were among the biggest losers due to negative developments like unsuccessful drug trials and poor financial results.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 5:36 pm

EUDA Health Holdings Limited (NASDAQ:EUDA), a Singapore-based digital health platform, has signed a letter of intent for a proposed merger with TheoremRx Inc., a private U.S.-based company focused on the development of new treatments for cancer and women's health conditions. The merger aims to bolster EUDA's market position and create significant value for shareholders. The completion of the merger is subject to various conditions, including regulatory approvals and the satisfaction of customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.